安捷伦，百时美施贵宝赢得FDA对癌症诊断测试的认可

2025-08-20 23:31

Agilent (NYSE:A) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its Dako Omnis test developed with Bristol Myers Squibb (NYSE:BMY) as a companion diagnostic to identify a type of colorectal cancer.
The test, also known as the MMR IHC Panel pharmDx, will therefore be used in the U.S. to identify CRC patients who are eligible for Bristol Myers’ (NYSE:BMY) cancer drugs, Opdivo as a single agent or in combination with Yervoy.
Specifically, the test, categorized as an immunohistochemical (IHC) panel, helps in identifying CRC patients lacking the mismatch repair pathway, a biological process that prevents cancer-causing genetic mutations.
According to Agilent (NYSE:A), Dako Omnis is the only FDA-cleared companion diagnostic IHC panel that can aid in identifying CRC patients indicated to receive Opdivo alone or in combination with Yervoy.

More on Agilent, Bristol-Myers Squibb